Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme
NCT ID: NCT01873469
Last Updated: 2019-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
102 participants
OBSERVATIONAL
2013-07-31
2018-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the study is to investigate the association of high \[11C\]MET tracer uptake before postoperative radiochemotherapy and concurrent temozolomide (TMZ) with time to recurrence in patients with glioblastoma multiforme. Also site of recurrence will be correlated with the \[11C\]MET imaging before and early during radiochemotherapy. All imaging information will be included in treatment planning or treatment decisions.
The study provides a basis for later radiation dose escalation trials on the base of \[11C\]MET imaging.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MET-PET for Newly Diagnosed Glioblastoma
NCT01867593
Pilot Viability of 11C-MET-PET as a Post-surgery Baseline Scan in High-grade Gliomas
NCT02585219
[18F]FPIA PET-CT in Glioblastoma Multiforme (GBM)
NCT05801159
PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?
NCT00628940
F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response
NCT00180193
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
\[11C\]MET-PET is expected to provide diagnostic (quantitative and spatial information) as well as prognostic information, to monitor treatment, to help stratification of patients for radiotherapeutic interventions such as dose-painting in order to optimize clinical applications and potentially improve the treatment outcome.
This study aims to provide the basis (e.g. optimal threshold value, sensitivity, specificity of MET uptake) for later intervention trials for treatment intensification, e.g. proton boost irradiation based on specific biomarkers.
The trial is a one-arm single-center, non-randomized observational (biomarker) study. After resection or biopsy, patients with newly diagnosed glioblastoma multiforme will receive a \[11C\]MET-PET/MRI scan before start of concurrent radiochemotherapy (\~1-4 weeks after surgery). A fusion with the planning CT for irradiation treatment planning will be performed. Postoperative radiotherapy will be applied in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total dose of 60 Gy (50 Gy and a boost of 10 Gy), with concomitant administration of daily Temozolomide (75 mg/m2 p.o.) from the 1st day to the last day of radiotherapy. Follow up with \[11C\]MET-PET/MRI will be performed every 3 months until recurrence or until death of the patient.
The uptake of \[11C\]MET-PET (as standard uptake value - SUV) in tumour and in normal contralateral grey matter before start of concurrent radiochemotherapy will be determined. For each tumour, the ratio between tracer uptake in the tumor and contralateral gray matter will be calculated (lesion-to-gray matter ratio \[l/g\]).
Primary end point will be time to recurrence (TTR) as function of \[11C\]MET uptake before chemoradiotherapy. Secondary endpoints will be overall survival; toxicity; C-Index/ROC curve (sensitivity, specificity, optimal threshold for normal/tumour tissue index), necrosis rate; site of recurrence.
The primary analysis will use the Cox proportional hazard model to establish the linear association between \[11C\]-MET and time-to-recurrence using a one-sided alpha = 0.1.
Parallel translational studies with orthotopic GBM xenografts (generated from the patients material in the trial) in nude mice will be performed in our laboratory to evaluate \[11C\]MET-PET as a tool for tailoring high precision radiotherapy. Histological, biological and genetic studies are planned to validate the imaging finding and to explore the underlying mechanisms.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Radiochemotherapy
glioblastoma patients with indication to radiochemotherapy
Radiochemotherapy
postoperative radiochemotherapy 60 Gy/ Temozolomide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radiochemotherapy
postoperative radiochemotherapy 60 Gy/ Temozolomide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* macroscopic total tumour resection or biopsy
* indication for combined radiochemotherapy with temozolomide
* patients are allowed to take part in other clinical trials at the same time
* beginning of radiochemotherapy no later than 7 weeks after surgery
* Karnofsky Performance Score ≥ 60, ECOG ≤2
* women with childbearing potential, (and men) adequate contraception
* ability of subject to understand character and individual consequences of the clinical trial
* written informed consent
Exclusion Criteria
* time interval of \> 7 weeks after surgery and beginning of radiochemotherapy
* patients who are not suitable for radiochemotherapy
* known other malignant disease that impacts prognosis of the patient and/or is likely to require treatment interfering with study therapy
* pregnant or lactating women
* patients with non-MRI compatible metal implants, pacemaker or non-MRI compatible external automatic defibrillators, insulin pumps, neurostimulators, cochlear implants
* Claustrophobic patients
* refusal of the patients to take part in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Technische Universität Dresden
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mechthild Krause
PD Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mechthild Krause, MD
Role: STUDY_CHAIR
Dresden University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology; and DKTK partner site Dresden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dresden University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Oncology; and DKTK partner site Dresden
Dresden, Saxony, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STR-PETra-2013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.